益肾通痹汤治疗类风湿关节炎的真实世界研究:前瞻性多中心队列方案
本文为一项前瞻性、多中心真实世界观察性研究方案,计划纳入324例活动性类风湿关节炎患者,比较益肾通痹汤联合csDMARDs与标准治疗(csDMARDs、tsDMARDs或bDMARDs)的疗效与安全性。主要结局为治疗12周时ACR20达标率,并于基线、第4周和第12周评估疾病活动度指标。
要点
- 益肾通痹汤联合csDMARDs与标准治疗对照,评估真实世界疗效与安全性。
- 主要结局为12周ACR20达标率,第4周和第12周评估DAS28、cDAI、sDAI等。
- 研究计划纳入324例活动性RA患者,在中国两个中心开展。
核心结论
- 该方案旨在通过前瞻性多中心真实世界研究全面评估益肾通痹汤治疗活动性类风湿关节炎的疗效与安全性。
- 前期3年RCT已确认益肾通痹汤治疗RA的临床疗效,并观察到第4周临床缓解率快于MTX。
研究设计与样本
- 计划纳入324例活动性类风湿关节炎患者。
- 一组接受益肾通痹汤联合csDMARDs,另一组接受标准治疗;标准治疗再分为csDMARDs、tsDMARDs和bDMARDs亚组。
主要发现
- 前期3年RCT确认益肾通痹汤治疗RA的临床疗效。
- 前期RCT观察到益肾通痹汤组第4周临床缓解率快于MTX组。
关键数值与推荐
- 主要结局为治疗第12周ACR20达标率。
- 于基线、第4周和第12周评估压痛关节数、肿胀关节数、疼痛评分、患者总体评价、医生总体评价、DAS28-ESR或DAS28-CRP、cDAI、sDAI及相关实验室数据。
- 报告每一例不良事件。
临床怎么用
- 为益肾通痹汤联合csDMARDs治疗活动性RA的真实世界疗效与安全性提供证据。
- 通过第4周和第12周疾病活动度指标动态评估,辅助临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: Rheumatoid arthritis (RA) is a globally challenging and refractory autoimmune disease, constituting a serious menace to human health. RA is characterized by recurrent pain and is difficult to resolve, necessitating prolonged medication for control. Yishen Tongbi decoction is a traditional Chinese herbal compound prescribed for treating RA. We have completed a 3-year RCT study that confirmed the clinical efficacy of Yishen Tongbi decoction for RA. Notably, we observed a faster clinical remission rate compared to MTX by week 4 of treatment. In our forthcoming study, we intend to conduct a comprehensive assessment of the efficacy and safety of Yishen Tongbi decoction in the real-world treatment of RA through a prospective study. Methods and analysis: This prospective, multicenter, real-world observational study will be conducted at two designated centers in China from October 2023 to August 2025. The study will include 324 patients with active rheumatoid arthritis. One group will receive Yishen Tongbi decoction combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The other group will receive standard treatment. Standard treatment can be further divided into subgroups: csDMARDs, targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), and biologic disease-modifying antirheumatic drugs (bDMARDs). In each group, the number of tender joints, number of swollen joints, pain score, patient global assessment, physician global assessment, disease activity index (DAS28-ESR or DAS28-CRP), clinical disease activity index (cDAI), simplified disease activity index (sDAI) and relevant laboratory data will be compared. Clinical indicators and disease activity of the patients will be assessed at baseline, week 4 and week 12 after the initiation of treatment. The primary outcome will be the American College of Rheumatology 20% improvement criteria (ACR20) attainment rate among patients at week 12 after treatment. Every adverse event will be reported. Ethics and dissemination: This study has been approved by the Ethics Committee of the first affiliated Hospital of Guangzhou University of traditional Chinese Medicine (NO.K-2023-009). The results of the study will be published in national and international peer-reviewed journals and at scientific conferences. The researchers will inform participants and other RA patients of the results through health education. Clinical Trial Registration: https://www.chictr.org.cn/index.html, identifier ChiCTR2300076073.
引用
- Liu L, Zhu F, Xin Y, et al. Real-world effects of Yishen Tongbi decoction for rheumatoid arthritis: protocol for a prospective, observational, multicenter cohort study with validation against double-blind, randomized, controlled trial. Front Pharmacol. 2024. PMID: 38410132. doi:10.3389/fphar.2024.1320578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。